Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.12068-12069 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12069 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 12068 |
| container_title | Blood |
| container_volume | 140 |
| creator | Soussain, Carole Issa, Samar Lewis, Katharine L Grommes, Christian Fox, Judith Ward, Renee Peterson, Caryn Cravets, Matt Mathias, Anita Sosa, Judith Kirby, Brian J Ding, Zhaoqing Yusuf, Isharat Rose, Mark J Steinberg, Marcos W Tun, Han W. |
| description | |
| doi_str_mv | 10.1182/blood-2022-158599 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_158599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122070690</els_id><sourcerecordid>S0006497122070690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1859-304c47b31c5006f2c01a51bae8170c28a85f7e08ce317675a9f80210c924374d3</originalsourceid><addsrcrecordid>eNp9UcGO0zAQtRBIlIUP4DYfsKEzTrxJ4LStYLeigmpbuEaOM9kapXZlh0r5Ub4Hd7tcOYxmNHpv9OY9Id4TfiCq5LwdvO8yiVJmpCpV1y_EjJSsMkSJL8UMEW-yoi7ptXgT4y9EKnKpZuLPLlg9gHWwCf4xcIwf4RY2ex0ZqJ1L2I6_uwl8D3cLRZKuQcMiaOuyDTseg3bjNWz8yOd-bx_3wwRbHtiM9sQJ7DpYhcAnDtG2A8Ni9xVWbm9bO_oAfaoHHvQxcjd_4D5ok9ZT0mIPOkzzLRvvujTB8tsW1tPhuPcH_XT1GQI_7RjYBx6tS3_8g7wVr3o9RH733K_Ejy-fd8v7bP39brW8XWeGkklZjoUpyjYno5I_vTRIWlGruaISjax0pfqSsTKcU3lTKl33FUpCU8siL4suvxJ0uWuCjzFw3xwvuhrC5hxM8xRMcw6muQSTOJ8uHE7CTpZDE41lZ7izIfnWdN7-h_0Xcf-XHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Soussain, Carole ; Issa, Samar ; Lewis, Katharine L ; Grommes, Christian ; Fox, Judith ; Ward, Renee ; Peterson, Caryn ; Cravets, Matt ; Mathias, Anita ; Sosa, Judith ; Kirby, Brian J ; Ding, Zhaoqing ; Yusuf, Isharat ; Rose, Mark J ; Steinberg, Marcos W ; Tun, Han W.</creator><creatorcontrib>Soussain, Carole ; Issa, Samar ; Lewis, Katharine L ; Grommes, Christian ; Fox, Judith ; Ward, Renee ; Peterson, Caryn ; Cravets, Matt ; Mathias, Anita ; Sosa, Judith ; Kirby, Brian J ; Ding, Zhaoqing ; Yusuf, Isharat ; Rose, Mark J ; Steinberg, Marcos W ; Tun, Han W.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-158599</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.12068-12069</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1859-304c47b31c5006f2c01a51bae8170c28a85f7e08ce317675a9f80210c924374d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Soussain, Carole</creatorcontrib><creatorcontrib>Issa, Samar</creatorcontrib><creatorcontrib>Lewis, Katharine L</creatorcontrib><creatorcontrib>Grommes, Christian</creatorcontrib><creatorcontrib>Fox, Judith</creatorcontrib><creatorcontrib>Ward, Renee</creatorcontrib><creatorcontrib>Peterson, Caryn</creatorcontrib><creatorcontrib>Cravets, Matt</creatorcontrib><creatorcontrib>Mathias, Anita</creatorcontrib><creatorcontrib>Sosa, Judith</creatorcontrib><creatorcontrib>Kirby, Brian J</creatorcontrib><creatorcontrib>Ding, Zhaoqing</creatorcontrib><creatorcontrib>Yusuf, Isharat</creatorcontrib><creatorcontrib>Rose, Mark J</creatorcontrib><creatorcontrib>Steinberg, Marcos W</creatorcontrib><creatorcontrib>Tun, Han W.</creatorcontrib><title>Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UcGO0zAQtRBIlIUP4DYfsKEzTrxJ4LStYLeigmpbuEaOM9kapXZlh0r5Ub4Hd7tcOYxmNHpv9OY9Id4TfiCq5LwdvO8yiVJmpCpV1y_EjJSsMkSJL8UMEW-yoi7ptXgT4y9EKnKpZuLPLlg9gHWwCf4xcIwf4RY2ex0ZqJ1L2I6_uwl8D3cLRZKuQcMiaOuyDTseg3bjNWz8yOd-bx_3wwRbHtiM9sQJ7DpYhcAnDtG2A8Ni9xVWbm9bO_oAfaoHHvQxcjd_4D5ok9ZT0mIPOkzzLRvvujTB8tsW1tPhuPcH_XT1GQI_7RjYBx6tS3_8g7wVr3o9RH733K_Ejy-fd8v7bP39brW8XWeGkklZjoUpyjYno5I_vTRIWlGruaISjax0pfqSsTKcU3lTKl33FUpCU8siL4suvxJ0uWuCjzFw3xwvuhrC5hxM8xRMcw6muQSTOJ8uHE7CTpZDE41lZ7izIfnWdN7-h_0Xcf-XHg</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Soussain, Carole</creator><creator>Issa, Samar</creator><creator>Lewis, Katharine L</creator><creator>Grommes, Christian</creator><creator>Fox, Judith</creator><creator>Ward, Renee</creator><creator>Peterson, Caryn</creator><creator>Cravets, Matt</creator><creator>Mathias, Anita</creator><creator>Sosa, Judith</creator><creator>Kirby, Brian J</creator><creator>Ding, Zhaoqing</creator><creator>Yusuf, Isharat</creator><creator>Rose, Mark J</creator><creator>Steinberg, Marcos W</creator><creator>Tun, Han W.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma</title><author>Soussain, Carole ; Issa, Samar ; Lewis, Katharine L ; Grommes, Christian ; Fox, Judith ; Ward, Renee ; Peterson, Caryn ; Cravets, Matt ; Mathias, Anita ; Sosa, Judith ; Kirby, Brian J ; Ding, Zhaoqing ; Yusuf, Isharat ; Rose, Mark J ; Steinberg, Marcos W ; Tun, Han W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1859-304c47b31c5006f2c01a51bae8170c28a85f7e08ce317675a9f80210c924374d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soussain, Carole</creatorcontrib><creatorcontrib>Issa, Samar</creatorcontrib><creatorcontrib>Lewis, Katharine L</creatorcontrib><creatorcontrib>Grommes, Christian</creatorcontrib><creatorcontrib>Fox, Judith</creatorcontrib><creatorcontrib>Ward, Renee</creatorcontrib><creatorcontrib>Peterson, Caryn</creatorcontrib><creatorcontrib>Cravets, Matt</creatorcontrib><creatorcontrib>Mathias, Anita</creatorcontrib><creatorcontrib>Sosa, Judith</creatorcontrib><creatorcontrib>Kirby, Brian J</creatorcontrib><creatorcontrib>Ding, Zhaoqing</creatorcontrib><creatorcontrib>Yusuf, Isharat</creatorcontrib><creatorcontrib>Rose, Mark J</creatorcontrib><creatorcontrib>Steinberg, Marcos W</creatorcontrib><creatorcontrib>Tun, Han W.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soussain, Carole</au><au>Issa, Samar</au><au>Lewis, Katharine L</au><au>Grommes, Christian</au><au>Fox, Judith</au><au>Ward, Renee</au><au>Peterson, Caryn</au><au>Cravets, Matt</au><au>Mathias, Anita</au><au>Sosa, Judith</au><au>Kirby, Brian J</au><au>Ding, Zhaoqing</au><au>Yusuf, Isharat</au><au>Rose, Mark J</au><au>Steinberg, Marcos W</au><au>Tun, Han W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>12068</spage><epage>12069</epage><pages>12068-12069</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-158599</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.12068-12069 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_158599 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T04%3A35%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trial%20in%20Progress:%20A%20Phase%201b/2%20Study%20of%20GB5121,%20a%20Brain-Penetrant,%20Potent,%20Highly%20Selective,%20and%20Irreversible%20BTK%20Inhibitor%20for%20Relapsed/Refractory%20Primary/Secondary%20CNS%20Lymphoma%20and%20Primary%20Vitreoretinal%20Lymphoma&rft.jtitle=Blood&rft.au=Soussain,%20Carole&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=12068&rft.epage=12069&rft.pages=12068-12069&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-158599&rft_dat=%3Celsevier_cross%3ES0006497122070690%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122070690&rfr_iscdi=true |